LONDON, UK – April 16, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Babraham Research Campus Ltd (BRCL) and is pleased to announce the placement of Dr. Rich Ferrie as Chief Executive Officer (CEO). Babraham Research Campus is one of the UK’s leading places to support early-stage bioscience enterprise. It is distinct in its co-location of over 60 bioscience companies alongside the Babraham Institute – creating an environment where world class research and business…
Some of the UK’s most ambitious early-stage life science companies are choosing Victoria House as their London base, adding fresh momentum to one of the capital’s most exciting life science communities.
Developed by Oxford Properties and Pioneer Group, the Bloomsbury Square building has attracted 24 innovative organisations since it launched last year, drawn by a rare and unique combination of high-quality incubator labs, flexible workspace, and a genuinely collaborative community.
Among the latest arrivals to Victoria House is Draig Therapeutics, a clinical-stage biopharmaceutical company…
Companies confirm that markers of weight loss and glycemic control are distinct in preliminary study, with multiple mechanisms identified that provide opportunities to guide indication extensionOXFORD, UK and PORTLAND, ME – 15 April 2026 – Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced that they have reached agreement to commercialize the outputs of PrecisionLife’s analysis of Ovation’s high quality GLP-1 receptor agonist dataset. The…
Agreement grants JH Health exclusive rights to use and distribute Atelerix’s portfolio of non-cryogenic preservation solutions in the region
Expands regional capabilities with funding for high-volume local manufacturing, as well as relevant regulatory filings and research collaborations
Strategic partnership enables access to new investment opportunities from Saudi sovereign funds
Newcastle, UK, 15 April 2026: Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has established…
Sandwich, UK — 15 April 2026: International contract research organisation ChemPartner has officially opened its first European scientific hub at Discovery Park, Sandwich, Kent. The company works with the biopharmaceutical industry to efficiently and rapidly bring life-changing drugs to market.
Founded in Shanghai in 2002, ChemPartner has more than 2,000 employees globally, most of whom are based in Asia. The company currently has seven UK employees, many of whom work hybrid, and is actively recruiting for a Senior Scientist to be based at Discovery Park.
ChemPartner’s Discovery Park facility…
ELRIG Announces Inaugural US Drug Discovery Conference
Free-to-attend event takes place at Pfizer in Cambridge, MA from 16–17 June
Drug Discovery USA 2026 to focus on emerging multifunctional small molecule and biologic approaches to drug difficult targets
Cambridge, UK, 14 April 2026: ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, today announced the launch of Drug Discovery USA 2026. The inaugural event, taking place at Pfizer in Cambridge, MA from 16–17 June, offers the drug discovery communities in Europe and the US the…
Amsbio reports how researchers at the Graduate School of Medicine, Kyoto University (Japan) have cultured patient-derived colorectal cancer cells in 3D using their MatriMix 511 extracellular matrix (ECM).
In this study** the researchers demonstrated that MatriMix supported robust cancer organoid formation, and that the organoids retained biologically relevant differences between tumour stages. By comparison, alternative matrices evaluated showed limited or no metastatic marker expression. The researchers concluded that MatriMix offers the ability to…
In the race to bring new therapeutics to market, the biggest hurdles aren’t just scientific—they’re operational. Fragmented data and information fatigue can slow down even the most promising pipelines.
To help biotech leaders bridge these gaps, Digital Science has launched a comprehensive resource hub focused on Advancing R&D Excellence. This suite of resources provides the framework needed to make confident, evidence-based decisions at every stage of discovery.
Inside the hub, you’ll find:
📘 The White Paper: A deep dive into "Structured Intelligence," exploring how AI is…
Tony JonesCEO, One Nucleus
Springing Forward in 2026 As the temperatures rise, flowers begin to bloom, and the deal flow reports keep coming; it feels like biotech may have a spring in its step. April storms and showers to dampen the mood are circling for many still; however, it is far from a universal bed of roses.
Thirty-six investment rounds were announced during Q1/2026, amounting to nearly £0.5Bn venture investment across the London and Cambridge areas alone in the sector. Notable rounds were secured by Mestag Therapeutics, Nuclera, Tenpoint…
Enables expression of active GPCRs in 48 hours
Panel supports screening to scale-up on eProtein Discovery
Cambridge, UK, and Boston MA, USA, 30 March 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery™ membrane protein workflow capabilities1, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of…